Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-Lung01: BL-B01D1 versus platinum chemotherapy after failure of third-generation EGFR-TKI in EGFR-mutant advanced non-squamous NSCLC
CTR20241709Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Progression-free survival by blinded independent central review. Started May 2024; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241709.